PMID- 19238013
OWN - NLM
STAT- MEDLINE
DCOM- 20090406
LR  - 20220914
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 32
IP  - 2
DP  - 2009 Feb-Mar
TI  - Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine 
      expressing RANTES elicits potent antitumor immunity.
PG  - 145-56
LID - 10.1097/CJI.0b013e318193d31e [doi]
AB  - Dendritic cells (DCs) are professional antigen (Ag)-presenting cells capable of 
      inducing immune responses to tumor Ags and, therefore, play a central role in the 
      induction of antitumor immunity. There is a large amount of evidence, however, 
      about paucity of tumor-associated DCs and that DCs' immunogenic functions are 
      suppressed in a tumor environment. Here we describe a potent in situ vaccine 
      targeting tumoral DCs in vivo. This vaccine comprised of an oncolytic adenovirus 
      expressing RANTES (regulated upon activation, normally T expressed, and 
      presumably secreted) (Ad-RANTES-E1A), enhanced tumor infiltration, and maturation 
      of Ag-presenting cells in vivo. In this study, we show that intratumoral 
      vaccinations with Ad-RANTES-E1A induced significant primary tumor growth 
      regression and blocked metastasis formation in JC and E.G-7 murine tumor models. 
      This vaccine recruited DCs, macrophages, natural killer cells, and CD8+ T cells 
      to the tumor site, and thus enhanced Ag-specific cytotoxic T lymphocyte responses 
      and natural killer cell responses. DCs purified from the Ad-RANTES-E1A-treated 
      E.G-7 tumors secreted significantly higher levels of interferon-gamma and 
      interleukin-12, as compared with control groups and more efficiently enhanced 
      CD8+ T-cell response. This in situ immunization strategy could be a potent 
      antitumor immunotherapy approach for aggressive established tumors.
FAU - Lapteva, Natalia
AU  - Lapteva N
AD  - Center for Cell and Gene Therapy, Department of Molecular and Human Genetics, 
      Baylor College of Medicine, Houston, TX, USA.
FAU - Aldrich, Melissa
AU  - Aldrich M
FAU - Weksberg, David
AU  - Weksberg D
FAU - Rollins, Lisa
AU  - Rollins L
FAU - Goltsova, Tatiana
AU  - Goltsova T
FAU - Chen, Si-Yi
AU  - Chen SY
FAU - Huang, Xue F
AU  - Huang XF
LA  - eng
GR  - R01AI68472/AI/NIAID NIH HHS/United States
GR  - R01 CA116677/CA/NCI NIH HHS/United States
GR  - R01 AI068472/AI/NIAID NIH HHS/United States
GR  - R01 CA11667/CA/NCI NIH HHS/United States
GR  - R01 CA090427/CA/NCI NIH HHS/United States
GR  - R01 CA90427/CA/NCI NIH HHS/United States
GR  - R01 CA100841/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Cancer Vaccines)
RN  - 0 (Chemokine CCL5)
RN  - 187348-17-0 (Interleukin-12)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Adenoviridae/genetics/immunology
MH  - Animals
MH  - CD8-Positive T-Lymphocytes/*immunology/metabolism
MH  - Cancer Vaccines/genetics/immunology/*therapeutic use
MH  - Chemokine CCL5/*genetics/immunology
MH  - Dendritic Cells/*immunology/virology
MH  - Female
MH  - Genetic Vectors/immunology
MH  - Immunotherapy
MH  - Interferon-gamma/blood
MH  - Interleukin-12/blood
MH  - Killer Cells, Natural/immunology/metabolism
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Neoplasms/genetics/*therapy/virology
MH  - Oncolytic Virotherapy
MH  - Oncolytic Viruses/genetics/*immunology
MH  - Ovalbumin/immunology
PMC - PMC4146345
MID - NIHMS622209
EDAT- 2009/02/25 09:00
MHDA- 2009/04/07 09:00
PMCR- 2014/08/27
CRDT- 2009/02/25 09:00
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2009/04/07 09:00 [medline]
PHST- 2014/08/27 00:00 [pmc-release]
AID - 00002371-200902000-00006 [pii]
AID - 10.1097/CJI.0b013e318193d31e [doi]
PST - ppublish
SO  - J Immunother. 2009 Feb-Mar;32(2):145-56. doi: 10.1097/CJI.0b013e318193d31e.